HomeCompareINRLF vs CHD

INRLF vs CHD: Dividend Comparison 2026

INRLF yields 63.90% · CHD yields 1.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 INRLF wins by $760.9K in total portfolio value
10 years
INRLF
INRLF
● Live price
63.90%
Share price
$3.13
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$787.3K
Annual income
$193,029.75
Full INRLF calculator →
CHD
CHD
● Live price
1.28%
Share price
$93.32
Annual div
$1.19
5Y div CAGR
23.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.4K
Annual income
$1,302.64
Full CHD calculator →

Portfolio growth — INRLF vs CHD

📍 INRLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodINRLFCHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, INRLF + CHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
INRLF pays
CHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

INRLF
Annual income on $10K today (after 15% tax)
$5,431.31/yr
After 10yr DRIP, annual income (after tax)
$164,075.29/yr
CHD
Annual income on $10K today (after 15% tax)
$108.62/yr
After 10yr DRIP, annual income (after tax)
$1,107.24/yr
At 15% tax rate, INRLF beats the other by $162,968.04/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of INRLF + CHD for your $10,000?

INRLF: 50%CHD: 50%
100% CHD50/50100% INRLF
Portfolio after 10yr
$406.8K
Annual income
$97,166.20/yr
Blended yield
23.88%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CHD right now

INRLF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-1.2
Piotroski
3/9
CHD
Analyst Ratings
18
Buy
15
Hold
1
Sell
Consensus: Buy
Price Target
$98.40
+5.4% upside vs current
Range: $82.00 — $110.00
Altman Z
4.9
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

INRLF buys
0
CHD buys
0
No recent congressional trades found for INRLF or CHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricINRLFCHD
Forward yield63.90%1.28%
Annual dividend / share$2.00$1.19
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%23.1%
Portfolio after 10y$787.3K$26.4K
Annual income after 10y$193,029.75$1,302.64
Total dividends collected$660.4K$5.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: INRLF vs CHD ($10,000, DRIP)

YearINRLF PortfolioINRLF Income/yrCHD PortfolioCHD Income/yrGap
1← crossover$17,090$6,389.78$10,857$157.30+$6.2KINRLF
2$28,492$10,205.59$11,814$196.49+$16.7KINRLF
3$46,387$15,901.41$12,887$245.97+$33.5KINRLF
4$73,830$24,195.53$14,097$308.68+$59.7KINRLF
5$114,988$35,990.20$15,473$388.49+$99.5KINRLF
6$175,424$52,386.69$17,046$490.55+$158.4KINRLF
7$262,396$74,691.78$18,861$621.76+$243.5KINRLF
8$385,177$104,413.37$20,973$791.47+$364.2KINRLF
9$555,383$143,243.74$23,454$1,012.51+$531.9KINRLF
10$787,290$193,029.75$26,398$1,302.64+$760.9KINRLF

INRLF vs CHD: Complete Analysis 2026

INRLFStock

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.

Full INRLF Calculator →

CHDConsumer Staples

Church & Dwight Co., Inc. develops, manufactures, and markets household, personal care, and specialty products. It operates through three segments: Consumer Domestic, Consumer International, and Specialty Products Division. The company offers cat litters, carpet deodorizers, laundry detergents, and baking soda, as well as other baking soda based products under the ARM & HAMMER brand; condoms, lubricants, and vibrators under the TROJAN brand; stain removers, cleaning solutions, laundry detergents, and bleach alternatives under the OXICLEAN brand; battery-operated and manual toothbrushes under the SPINBRUSH brand; home pregnancy and ovulation test kits under the FIRST RESPONSE brand; depilatories under the NAIR brand; oral analgesics under the ORAJEL brand; laundry detergents under the XTRA brand; gummy dietary supplements under the L'IL CRITTERS and VITAFUSION brands; dry shampoos under the BATISTE brand; water flossers and replacement showerheads under the WATERPIK brand; FLAWLESS products; cold shortening and relief products under the ZICAM brand; and oral care products under the THERABREATH brand. Its specialty products include animal productivity products, such as MEGALAC rumen bypass fat, a supplement that enables cows to maintain energy levels during the period of high milk production; BIO-CHLOR and FERMENTEN, which are used to reduce health issues associated with calving, as well as provides needed protein; and CELMANAX refined functional carbohydrate, a yeast-based prebiotic. The company offers sodium bicarbonate; and cleaning and deodorizing products. It sells its consumer products through supermarkets, mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar and other discount stores, pet and other specialty stores, and websites and other e-commerce channels; and specialty products to industrial customers and livestock producers through distributors. The company was founded in 1846 and is headquartered in Ewing, New Jersey.

Full CHD Calculator →
📬

Get this INRLF vs CHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

INRLF vs SCHDINRLF vs JEPIINRLF vs OINRLF vs KOINRLF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.